ViennaLab Diagnostics GmbH products

BRAF encodes a serine/threonine protein kinase, which plays an important role in signaling pathways involved in cell proliferation and differentiation. Determination of BRAF V600 mutational status is recommended in metastatic colorectal cancer (mCRC) at the same time as RAS mutational status for prognostic assessment (and/or potential selection for clinical trials). Testing of patients with metastatic melanoma or advanced non-small cell lung cancer for BRAF V600 mutations prior to treatment is recommended, as BRAF V600 mutation positive patients may benefit from BRAF inhibitor therapy (e.g. dabrafenib, trametinib, vemurafenib).

A reliable tool to personalize therapy of lung cancer patients with acquired TKI-resistance mutation T790M in the EGFR gene

NSCLC comprises approximately 85% of all lung cancers. Tumor specimens from patients should be tested for the presence of EGFR mutations prior to TKI treatment. The EGFR XL StripAssay® and EGFR T790M RealFast™ Assay are designed to assist clinicians in the stratification of patients considered for TKI therapy.

Alpha-1 Antitrypsin (AAT) deficiency is an inherited disorder, which is still an underappreciated, but treatable cause of chronic obstructive pulmonary disease (COPD). The AAT RealFast™ Assay is designed for the simultaneous detection of protease inhibitor (PI) variants *S and *Z of the SERPINA1 gene, representing the most frequent alleles associated with AAT deficiency.

Congenital adrenal hyperplasia (CAH) is an inherited disorder affecting steroid hormone synthesis. The CAH StripAssay^® detects the most common point mutations, whereas the CAH RealFast™ CNV Assay identifies copy number variations (CNVs) in the CYP21A2 gene in patients with CAH. For comprehensive genetic analysis both assays should be used in combination.